About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: November 2014
Upclose Look at Pharma and Twitter – A Brief Profile
Last week I posted about the update to the database of pharma and social media use with respect to the increase in audience over last year. While FDA’s OPDP was so complacent in coming forth in guidelines, the number of … Continue reading
Posted in New and Social Media
Comments Off on Upclose Look at Pharma and Twitter – A Brief Profile
Weekly Roundup 11.7.14
It is a lovely autumn in our nation’s capital – at least looking at the trees and the light. It is always remarkable how the light angles change and the sun will suddenly appear beneath clouds instead of over them … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 11.7.14
Pharma Twitter Followers on the Rise
As a highly regulated industry, the pharmaceutical sector was very slow to embrace social media and given the very slow and highly restrictive guidance put out by FDA on that topic, branded participation – particularly on Twitter – is going … Continue reading
Posted in Social Media
4 Comments